Science

Vincent Rajkumar: 15 Years Since We Changed Myeloma Care with Less Dexamethasone

Vincent Rajkumar/X

May 15, 2025, 09:44

Vincent Rajkumar: 15 Years Since We Changed Myeloma Care with Less Dexamethasone

Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, shared a post on X:

“At ECOG-ACRIN Cancer Research Group meeting today, I recollected one of the most consequential clinical trials in myeloma.

15 years ago we demonstrated that we can save a lot of lives by just reducing dexamethasone dose.”

Title: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors: Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp

You can read the Full Article on The Lancet Oncology

Vincent Rajkumar: 15 Years Since We Changed Myeloma Care with Less Dexamethasone

More posts featuring Myeloma.

cancer David H. Vesole David S Siegel dexamethasone ECOG-ACRIN Cancer Research Group Michael E Williams Michael Katz Myeloma Natalie S Callander OncoDaily Oncology Philip R Greipp Rafael Fonseca Rafat Abonour Susanna Jacobus Vincent Rajkumar

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot